10 de julho de 2026

Cardiac amyloidosis represents a unique disease process characterized by amyloid fibril deposition within the myocardialextracellular space. Advances in multimodality cardiac imaging enable accurate diagnosis and facilitate prompt initiationof disease-modifying therapies. Furthermore, rapid advances in multimodality imaging have enriched understanding ofthe underlying pathogenesis, enhanced prognostication, and resulted in the development of imaging-based markers thatreflect the amyloid […]

Transthyretin amyloid cardiomyopathy is caused by the deposition of transthyretin amyloid fibrils in the myocardium. The deposition occurs when wild-type or variant transthyretin becomes unstable and misfolds. Tafamidis binds to transthyretin, preventingtetramer dissociation and amyloidogenesis.

This document was created by an American Society of Echocardiography Amyloidosis Taskforce as a practical accompaniment to therecently published multisociety Expert Consensus Recommendationsfor Multimodality Imaging in Cardiac Amyloidosis.1,2 In this document we will outline the common echocardiographic imaging findings of cardiac amyloidosis (CA), highlighting red flags that shouldraise suspicion for the diagnosis. We will also

Posicionamento sobre Diagnóstico e Tratamento daAmiloidose Cardíaca – 2021 Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis – 2021Realização: Departamento de Insuficiência Cardíaca (DEIC) e Grupo de Estudos em Miocardiopatias (GEMIC)da Sociedade Brasileira de Cardiologia (SBC)Conselho de Normatizações e Diretrizes (2020-2021): Antonio Carlos Sobral Sousa, Aurora Felice de CastroIssa, Bruno Ramos Nascimento, Harry Corrêa

Position Statement on Multimodality Cardiac Imaging in Patients with Systemic Diseases – 2026Realização: Departamento de Imagem Cardiovascular da Sociedade Brasileira de Cardiologia (DIC/SBC)Autores do Posicionamento: Viviane Tiemi Hotta,1,2 Isabela Bispo Santos da Silva Costa,3 Renata ChristianMartins Felix,4,5 Maria Estefânia Otto Bosco,6,7 Minna Moreira Dias Romano,8 Nathalia Conci Santorio,1Simone Cristina Soares Brandão,9 Daniela do Carmo Rassi

Dermot Phelan, Patrick Collier, Paaladinesh Thavendiranathan, Zoran B Popovi
c,Mazen Hanna, Juan Carlos Plana, Thomas H Marwick, James D ThomasABSTRACTBackground The diagnosis of cardiac amyloidosis (CA) ischallenging owing to vague symptomatology and nonspecific echocardiographic findings.Objective To describe regional patterns in longitudinalstrain (LS) using two-dimensional speckle-trackingechocardiography in CA and to test the hypothesis thatregional differences would help

Pablo Garcia-Pavia 1,2,3,*†, Esther Gonzalez-Lopez1,2,†, Lisa J. Anderson4,Francesco Cappelli5, Thibaud Damy 6, Marianna Fontana7,Jose Gonzalez-Costello8,9, Ruxandra Jurcut 10,11, Olivier Lairez12,Peter van der Meer 13, Marco Merlo 14,15, Stefano Perlini16,and Antoni Bayes-Genis 2,17,18,*1Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, GUARD-HEART ERN, Manuel de Falla, 2, Madrid 28222, Spain; 2CIBER Cardiovascular,Instituto de Salud Carlos

Perry Elliott , MD; Brian M. Drachman, MD; Stephen S. Gottlieb , MD; James E. Hoffman, MD; Scott L. Hummel , MD;Daniel J. Lenihan , MD; Ben Ebede, MS, MBA; Balarama Gundapaneni, MS; Benjamin Li, MS; Marla B. Sultan, MD, MBA;Sanjiv J. Shah , MDBACKGROUND: Tafamidis is approved in many countries for the treatment of